Table 4 Replication and pooled analysis of the association of VEGFA rs943080 with visual acuity changes during 12 months of ranibizumab treatment.

From: A prospective multicenter study on genome wide associations to ranibizumab treatment outcome for age-related macular degeneration

Stage

BETA (95% CI)

P

BETA (95% CI)*

P*

Discovery stage

0.06 (0.01–0.11)

0.022

0.06 (0.01–0.11)

0.031

Replication stage

−0.06 (−0.11– −0.001)

0.047

−0.08 (−0.13– −0.02)

0.0065

Pooled analysis

0.01 (−0.03–0.05)

0.62

0.00 (−0.04–0.03)

0.86

  1. *Adjusted for age and sex, CI: confidence interval.
Back to article page